Miguel Perales MD
@drmiguelperales.bsky.social
Chief Adult BMT MSKCC | Past-President ASTCT | Board Member NMDP | Chair Committee Transplant/Cell Ther ALLIANCE | Immigrant 🇪🇸🇬🇧 #MedSky Opinions mine/not MSK
https://www.mskcc.org/cancer-care/doctors/miguel-angel-perales
https://www.mskcc.org/cancer-care/doctors/miguel-angel-perales
Pinned
Very honored to give Ciril Rozmán Lecture at the annual meeting of the Spanish Society of Hematology and Hemotherapy @sehhematologia.bsky.social. The Ciril Rozmán Award recognizes a foreign hematologist who has made high-level scientific contributions and has had close ties with Spanish experts.
Reposted by Miguel Perales MD
We're excited to share that we've been recognized as #1 in oncology on @newsweek.com's World's Best Specialized Hospitals List.
bit.ly/4nefIFv
bit.ly/4nefIFv
October 22, 2025 at 4:58 PM
We're excited to share that we've been recognized as #1 in oncology on @newsweek.com's World's Best Specialized Hospitals List.
bit.ly/4nefIFv
bit.ly/4nefIFv
Reposted by Miguel Perales MD
Congratulations to this year’s recipients of the MSK 2025 Paul Marks Prize for Cancer Research: Dr. @oawlab.bsky.social, of MSK; Dr. Andrea Ablasser, of EPFL; and Dr. Christina Curtis, of @stanfordmedicine.bsky.social.
Learn more about the winners: bit.ly/47y8HLb
Learn more about the winners: bit.ly/47y8HLb
November 4, 2025 at 2:42 PM
Congratulations to this year’s recipients of the MSK 2025 Paul Marks Prize for Cancer Research: Dr. @oawlab.bsky.social, of MSK; Dr. Andrea Ablasser, of EPFL; and Dr. Christina Curtis, of @stanfordmedicine.bsky.social.
Learn more about the winners: bit.ly/47y8HLb
Learn more about the winners: bit.ly/47y8HLb
Reposted by Miguel Perales MD
🚨The FDA approved durvalumab in combination with a chemotherapy regimen before & after surgery for people with early stage #gastriccancer and gastroesophageal #cancers. Congrats to Yelena Janjiagian, who led the trial that resulted the approval! @mskcancercenter.bsky.social
➡️ bit.ly/480s8MO
➡️ bit.ly/480s8MO
November 26, 2025 at 1:14 AM
🚨The FDA approved durvalumab in combination with a chemotherapy regimen before & after surgery for people with early stage #gastriccancer and gastroesophageal #cancers. Congrats to Yelena Janjiagian, who led the trial that resulted the approval! @mskcancercenter.bsky.social
➡️ bit.ly/480s8MO
➡️ bit.ly/480s8MO
Reposted by Miguel Perales MD
#ICYMI: 36 MSK researchers are among the @clarivateag.bsky.social list of Highly Cited Researchers 2025, which identifies scientists who have demonstrated significant and broad influence in their field(s) of research.
Memorial Sloan Kettering Cancer Center Applauds Highly Cited Researchers 2025
In 2025, MSK was again ranked among the top organizations with the greatest number of highly cited scientific researchers worldwide, according to the annual list of Highly Cited Researchers, published...
www.mskcc.org
November 12, 2025 at 5:17 PM
#ICYMI: 36 MSK researchers are among the @clarivateag.bsky.social list of Highly Cited Researchers 2025, which identifies scientists who have demonstrated significant and broad influence in their field(s) of research.
Reposted by Miguel Perales MD
🚨 Last call: The deadline to apply for the Cancer Biology or Cancer Engineering #PhD programs at MSK's Gerstner Sloan Kettering Graduate School of Biomedical Sciences is 12/1.
Don't miss the opportunity to make the next groundbreaking discovery in cancer and biomedical sciences. Apply ⬇️
Don't miss the opportunity to make the next groundbreaking discovery in cancer and biomedical sciences. Apply ⬇️
Admission to the PhD Programs
Gerstner Sloan Kettering offers a unique opportunity to train with some of the world’s leading researchers while developing a deep understanding of today’s clinical challenges. We are looking for high...
www.sloankettering.edu
November 19, 2025 at 4:48 PM
🚨 Last call: The deadline to apply for the Cancer Biology or Cancer Engineering #PhD programs at MSK's Gerstner Sloan Kettering Graduate School of Biomedical Sciences is 12/1.
Don't miss the opportunity to make the next groundbreaking discovery in cancer and biomedical sciences. Apply ⬇️
Don't miss the opportunity to make the next groundbreaking discovery in cancer and biomedical sciences. Apply ⬇️
Reposted by Miguel Perales MD
Congratulations to Dr. Lorenzo Falchi of @mskcancercenter.bsky.social on the FDA approval of epcoritamab-bysp with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma! A huge win for those with the condition. Dr. Falchi will present phase 3 trial data at #ASH25.
The @fda.gov approved the immunotherapy epcoritamab-bysp with lenalidomide and rituximab for relapsed or refractory follicular lymphoma: buff.ly/JNJZKMb
FDA approves epcoritamab-bysp for follicular lymphoma indications
FDA approves epcoritamab-bysp for follicular lymphoma indications
www.fda.gov
November 18, 2025 at 7:14 PM
Congratulations to Dr. Lorenzo Falchi of @mskcancercenter.bsky.social on the FDA approval of epcoritamab-bysp with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma! A huge win for those with the condition. Dr. Falchi will present phase 3 trial data at #ASH25.
Reposted by Miguel Perales MD
🚨: A clinical trial that resulted in a new @fda.gov approval, led by Dr. Yelena Janjigian, investigated using the immunotherapy treatment #durvalumab (INFINZI) in combination w/a standard-of-care chemotherapy regimen before & after surgery for people w/stomach & esophagus cancer.
bit.ly/3XVQC3G
bit.ly/3XVQC3G
November 26, 2025 at 2:58 PM
🚨: A clinical trial that resulted in a new @fda.gov approval, led by Dr. Yelena Janjigian, investigated using the immunotherapy treatment #durvalumab (INFINZI) in combination w/a standard-of-care chemotherapy regimen before & after surgery for people w/stomach & esophagus cancer.
bit.ly/3XVQC3G
bit.ly/3XVQC3G
Reposted by Miguel Perales MD
5 years ago I started a team competition on Twitter to raise $ to fight hunger.
@tmprowell.bsky.social gave us a hashtag & much needed organization
Our team of teen volunteers work wonders in the background & we’ve raised >$3.1 million!
Competition starts tomorrow, join us?
HCWvsHunger.org
@tmprowell.bsky.social gave us a hashtag & much needed organization
Our team of teen volunteers work wonders in the background & we’ve raised >$3.1 million!
Competition starts tomorrow, join us?
HCWvsHunger.org
Healthcare Workers vs Hunger
Healthcare workers vs Hunger is an annual friendly competition between teams of healthcare workers to help relieve food insecurity.
HCWvsHunger.org
November 26, 2025 at 7:55 PM
5 years ago I started a team competition on Twitter to raise $ to fight hunger.
@tmprowell.bsky.social gave us a hashtag & much needed organization
Our team of teen volunteers work wonders in the background & we’ve raised >$3.1 million!
Competition starts tomorrow, join us?
HCWvsHunger.org
@tmprowell.bsky.social gave us a hashtag & much needed organization
Our team of teen volunteers work wonders in the background & we’ve raised >$3.1 million!
Competition starts tomorrow, join us?
HCWvsHunger.org
Reposted by Miguel Perales MD
This is amazing!
Australia’s latest cervical cancer report is wild:
Zero cases in women under 25 for the first time ever — a milestone researchers say is almost entirely due to HPV vaccination.
But vaccination rates are slipping, and experts warn urgent
#BlueSky #NewsSky #MedSky #SciSky #IDSky #ObSky #PedsSky
Zero cases in women under 25 for the first time ever — a milestone researchers say is almost entirely due to HPV vaccination.
But vaccination rates are slipping, and experts warn urgent
#BlueSky #NewsSky #MedSky #SciSky #IDSky #ObSky #PedsSky
2025 Cervical Cancer Elimination Progress Report | C4
Australia’s progress towards the elimination of cervical cancer as a public health problem
report.cervicalcancercontrol.org.au
November 26, 2025 at 4:56 PM
This is amazing!
Reposted by Miguel Perales MD
Your go-to social media guide for #ASH25 is here. Find tips on following updates, taking part in conversations, using the official hashtags, and entering fun challenges with #ASHNewsDaily.
Read now: https://ow.ly/tEgJ50XxAP6
#HemeSky #ASHaiku #ASHKudos #ASHRunWalk #ASHScavengerHunt
Read now: https://ow.ly/tEgJ50XxAP6
#HemeSky #ASHaiku #ASHKudos #ASHRunWalk #ASHScavengerHunt
November 25, 2025 at 5:15 PM
Your go-to social media guide for #ASH25 is here. Find tips on following updates, taking part in conversations, using the official hashtags, and entering fun challenges with #ASHNewsDaily.
Read now: https://ow.ly/tEgJ50XxAP6
#HemeSky #ASHaiku #ASHKudos #ASHRunWalk #ASHScavengerHunt
Read now: https://ow.ly/tEgJ50XxAP6
#HemeSky #ASHaiku #ASHKudos #ASHRunWalk #ASHScavengerHunt
Reposted by Miguel Perales MD
Calling all rising juniors & seniors: Interested in biological or biomedical research? Applications for our ’26 Summer Undergraduate Research Experience Program are now open! Nine weeks, hands-on research, & mentorship from some of the nation’s top scientists — learn more: bit.ly/CechFellows
Summer Undergraduate Research Experience | HHMI
The Cech Fellows Program is a paid, nine-week summer research experience empowering the next generation of scientific leaders.
bit.ly
November 18, 2025 at 2:44 PM
Calling all rising juniors & seniors: Interested in biological or biomedical research? Applications for our ’26 Summer Undergraduate Research Experience Program are now open! Nine weeks, hands-on research, & mentorship from some of the nation’s top scientists — learn more: bit.ly/CechFellows
Notice from @nysdoh.bsky.social #vaccinessavelives
November 25, 2025 at 2:24 AM
Notice from @nysdoh.bsky.social #vaccinessavelives
Reposted by Miguel Perales MD
Applications for the 2026 Leadership Course are now open! Receive 1:1 training and development to help you in your new or future leadership role from current program directors in the HCT and cellular therapy field. Apply by Nov. 24: https://ow.ly/Owvg50Xeg4e
October 20, 2025 at 4:01 PM
Applications for the 2026 Leadership Course are now open! Receive 1:1 training and development to help you in your new or future leadership role from current program directors in the HCT and cellular therapy field. Apply by Nov. 24: https://ow.ly/Owvg50Xeg4e
Reposted by Miguel Perales MD
Whether you're a clinician, researcher, nurse or trainee, ASTCT membership gives you access to specialized educational content, CE opportunities and significant savings on meetings, including the 2026 Tandem Meetings.
Join or renew now for access to benefits through 2026: https://ow.ly/3ZUn50X594m
Join or renew now for access to benefits through 2026: https://ow.ly/3ZUn50X594m
October 23, 2025 at 6:30 PM
Whether you're a clinician, researcher, nurse or trainee, ASTCT membership gives you access to specialized educational content, CE opportunities and significant savings on meetings, including the 2026 Tandem Meetings.
Join or renew now for access to benefits through 2026: https://ow.ly/3ZUn50X594m
Join or renew now for access to benefits through 2026: https://ow.ly/3ZUn50X594m
Reposted by Miguel Perales MD
Influenza remains an important cause of illness and death. In a phase 3 trial, a nucleoside-modified mRNA (modRNA) quadrivalent vaccine was found to be superior to a standard quadrivalent vaccine in preventing influenza illness. Full trial results and Research Summary: nej.md/43udoTG
November 23, 2025 at 2:00 PM
Influenza remains an important cause of illness and death. In a phase 3 trial, a nucleoside-modified mRNA (modRNA) quadrivalent vaccine was found to be superior to a standard quadrivalent vaccine in preventing influenza illness. Full trial results and Research Summary: nej.md/43udoTG
Reposted by Miguel Perales MD
For 40+ years, the ASH Scholar Award has helped jumpstart careers in hematology—funding 678 awards, $82M in research, and $3B in follow-on funding. Learn more: https://bit.ly/4idJLvV
#ASHAwards
#ASHAwards
November 20, 2025 at 8:00 PM
For 40+ years, the ASH Scholar Award has helped jumpstart careers in hematology—funding 678 awards, $82M in research, and $3B in follow-on funding. Learn more: https://bit.ly/4idJLvV
#ASHAwards
#ASHAwards
Reposted by Miguel Perales MD
Explore everything #ASH25 has to offer beyond the program!
Update your headshot 🩸Get the latest in education and fASHion at the ASH Store 👗📚
Connect in lounges and networking spaces 🤝💬
Have fun 🎉and rest 😌🛋️!
🔗On-site amenities: https://ow.ly/Cs9r50XsOEa
#HemeSky #MedSky #Hematology
Update your headshot 🩸Get the latest in education and fASHion at the ASH Store 👗📚
Connect in lounges and networking spaces 🤝💬
Have fun 🎉and rest 😌🛋️!
🔗On-site amenities: https://ow.ly/Cs9r50XsOEa
#HemeSky #MedSky #Hematology
November 21, 2025 at 3:05 PM
Explore everything #ASH25 has to offer beyond the program!
Update your headshot 🩸Get the latest in education and fASHion at the ASH Store 👗📚
Connect in lounges and networking spaces 🤝💬
Have fun 🎉and rest 😌🛋️!
🔗On-site amenities: https://ow.ly/Cs9r50XsOEa
#HemeSky #MedSky #Hematology
Update your headshot 🩸Get the latest in education and fASHion at the ASH Store 👗📚
Connect in lounges and networking spaces 🤝💬
Have fun 🎉and rest 😌🛋️!
🔗On-site amenities: https://ow.ly/Cs9r50XsOEa
#HemeSky #MedSky #Hematology
Reposted by Miguel Perales MD
Last chance to submit your comment! Public comments for draft recommendations for myelofibrosis close on November 24.
Learn more: https://ow.ly/ukja50Xf62F
Learn more: https://ow.ly/ukja50Xf62F
November 21, 2025 at 7:00 PM
Last chance to submit your comment! Public comments for draft recommendations for myelofibrosis close on November 24.
Learn more: https://ow.ly/ukja50Xf62F
Learn more: https://ow.ly/ukja50Xf62F
Reposted by Miguel Perales MD
Join Dr. Sewaralthahab to explore the classical hematology sessions sure to have a full house — including a guidelines session, abstract presentation, and Education Program session.
🔗#ASH25 Through the Lens of a Classical Hematologist: ow.ly/H3mi50XvNJJ #HemeSky #MedSky
6/6
🔗#ASH25 Through the Lens of a Classical Hematologist: ow.ly/H3mi50XvNJJ #HemeSky #MedSky
6/6
November 22, 2025 at 12:45 PM
Join Dr. Sewaralthahab to explore the classical hematology sessions sure to have a full house — including a guidelines session, abstract presentation, and Education Program session.
🔗#ASH25 Through the Lens of a Classical Hematologist: ow.ly/H3mi50XvNJJ #HemeSky #MedSky
6/6
🔗#ASH25 Through the Lens of a Classical Hematologist: ow.ly/H3mi50XvNJJ #HemeSky #MedSky
6/6
Reposted by Miguel Perales MD
Immunotherapies stand out as a defining theme of #ASH25. @majorajay.bsky.social previews three hot Education Program sessions.
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
November 22, 2025 at 12:45 PM
Immunotherapies stand out as a defining theme of #ASH25. @majorajay.bsky.social previews three hot Education Program sessions.
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
Reposted by Miguel Perales MD
📰 Your official #ASH25 news is here! The preview issue of #ASHNewsDaily is now live, with teasers of some can’t-miss sessions. 🧵
First up: Editor-in-Chief Joselle Cook, MBBS, welcomes you to the annual meeting! 🔗 ow.ly/IU2J50XvNOY #HemeSky #MedSky
1/6
First up: Editor-in-Chief Joselle Cook, MBBS, welcomes you to the annual meeting! 🔗 ow.ly/IU2J50XvNOY #HemeSky #MedSky
1/6
November 22, 2025 at 12:45 PM
📰 Your official #ASH25 news is here! The preview issue of #ASHNewsDaily is now live, with teasers of some can’t-miss sessions. 🧵
First up: Editor-in-Chief Joselle Cook, MBBS, welcomes you to the annual meeting! 🔗 ow.ly/IU2J50XvNOY #HemeSky #MedSky
1/6
First up: Editor-in-Chief Joselle Cook, MBBS, welcomes you to the annual meeting! 🔗 ow.ly/IU2J50XvNOY #HemeSky #MedSky
1/6
Kennedy Says He Told C.D.C. to Change Website’s Language on Autism and Vaccines www.nytimes.com/2025/11/21/u...
Kennedy Says He Told C.D.C. to Change Website’s Language on Autism and Vaccines
www.nytimes.com
November 22, 2025 at 1:19 PM
Kennedy Says He Told C.D.C. to Change Website’s Language on Autism and Vaccines www.nytimes.com/2025/11/21/u...
Reposted by Miguel Perales MD
Discussion of FDAs new super-rapid review process and criteria to get such rapid reviews. www.statnews.com/2025/11/21/f... via @statnews.com
The Trump administration is turning drug review into make-a-deal
“FDA decision-making may be reduced to a sequence of ‘make-a-deals’ with Trump, his FDA, or even political allies,” experts warn.
www.statnews.com
November 21, 2025 at 1:08 PM
Discussion of FDAs new super-rapid review process and criteria to get such rapid reviews. www.statnews.com/2025/11/21/f... via @statnews.com
F.D.A. Names Agency Veteran to Run Drug Division www.nytimes.com/2025/11/11/s...
F.D.A. Names Agency Veteran to Run Drug Division
www.nytimes.com
November 12, 2025 at 12:24 PM
F.D.A. Names Agency Veteran to Run Drug Division www.nytimes.com/2025/11/11/s...